Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said. - Investor's Business Daily
- Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said. Investor's Business Daily
- Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline CNBC
- Novo drug trial fail deals setback to bid to expand beyond obesity Reuters
- Novo Nordisk Shares Drop After Drug Candidate Fails in Trial WSJ
- Novo Nordisk inflammation-targeting drug misses mark in heart disease study STAT
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events